Description

The recombinant humanized anti-CD20 monoclonal antibody is an antibody produced via CHO stable cell line expression system, specifically targeting the CD20 molecule on B-cell surfaces. Through high-affinity binding, it triggers complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP), inducing mitochondrial pathway apoptosis in CD20+ B cells.

In ex vivo B-cell depletion systems, this antibody efficiently eliminates non-Hodgkin lymphoma cells and autoreactive B-cell clones.

Its Fc segment, engineered with glycosylation modifications (e.g., enhanced fucosylation), strengthens binding to FcγRIIIa (V158 variant), significantly enhancing NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC).

In CAR-T therapy development, it serves as an ex vivo B-cell depletion agent to optimize T-cell starting purity and mitigate cytokine release syndrome (CRS) risks by modulating residual B-cell levels.

Manufactured using animal component-free media and affinity chromatography, the product complies with release specifications through stringent control of host protein residuals, host DNA residuals, and endotoxin levels.

It is suitable for B-cell lymphoma immunotherapy, autoimmune disease cell therapies, and bispecific antibody development.

Specifications

Test Item	Specification	Results
Appearance	Should be a colorless and transparent liquid	Compliance
Identity	The electrophoretic bands should be consistent with the molecular weight of the product	Compliance
Visible Particle	Should be no visible particle	Compliance
pH	6.5 – 7.5	7.5
Concentration	1.0 – 1.5 mg/mL	1.0 mg/mL
Purity	>90.0%	Compliance
Endotoxin	<0.1 EU/μg	<0.1 EU/μg
Mycoplasma	Should be negative	Negative
Sterility	No growth	No growth

Features

Recombinant humanized anti-CD20 monoclonal antibody produced in a stable CHO cell expression system, specifically recognizing the CD20 antigen on human B-cell surfaces.
High-affinity binding to CD20 efficiently induces B-cell depletion through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP).
Fc-mediated effector functions support NK cell-driven ADCC, enabling robust elimination of CD20⁺ target cells in ex vivo systems.
Effectively eliminates malignant and autoreactive B-cell populations, supporting downstream immune modulation and functional immune cell enrichment.
Manufactured using animal component-free media and affinity chromatography to ensure consistent purity, low host cell residuals, and controlled endotoxin levels.
Suitable for research applications requiring reliable and reproducible B-cell targeting in immunology and cell therapy development workflows.

Applications

Ex vivo B-cell depletion

Ex vivo B-cell depletion from PBMCs or mixed immune cell populations.

CD20 cytotoxicity mechanisms

Functional studies of CD20-mediated B-cell cytotoxicity mechanisms.

B-cell malignancy research

Non-Hodgkin lymphoma and B-cell malignancy research.

CAR-T manufacturing support

Removal of residual B cells during CAR-T cell manufacturing to improve T-cell starting purity.

Autoimmune disease research

Autoimmune disease research, including depletion of autoreactive B-cell clones.

Antibody & bispecific strategies

Development and evaluation of antibody-based and bispecific immunotherapy strategies.

Storage

Store at 2–8 °C. Do not freeze. Protect from light.

Documents

📄 GMP-TL502 Data Sheet 📄 GMP-TL502 SDS 📄 GMP-TL502 COA

Attention

For research and manufacturing purposes only.

Anti-Human CD20 Monoclonal Antibody (CD20 Mab)